



***De novo* L-cysteine biosynthesis as a
target for antibiotic development:
identification of
Pseudomonas aeruginosa
CysH inhibitors *via* a
multidisciplinary approach**





Finanziato
dall'Unione europea
NextGenerationEU



Ministero
dell'Università
e della Ricerca




Italiadomani
PIANO NAZIONALE
DI RIPRESA E RESILIENZA



World Health
Organization



Antimicrobial resistance



More than
35000 deaths


Each year, more than 35 000 people die from antibiotic-resistant infections in the European Union, Iceland and Norway. This is equivalent to the number of passengers on 13 cruise ships.

Antibiotic resistance is a silent pandemic and a growing threat to human health.



Over **70 %**
healthcare-associated
infections

Over 70% of the health impact of antibiotic-resistant infections is directly linked to healthcare-associated infections. This could be minimized through adequate infection prevention and control measures, as well as antibiotic stewardship in healthcare settings.



Centers for Disease Control and Prevention
CDC 24/7: Saving Lives, Protecting People™



Finanziato
dall'Unione europea
NextGenerationEU



Ministero
dell'Università
e della Ricerca



Italiadomani
PIANO NAZIONALE
DI RIPRESA E RESILIENZA

Antimicrobial resistance

Critical group



Enterobacteriales
carbapenem-resistant



Enterobacteriales
third-generation
cephalosporin-resistant



*Acinetobacter
baumannii*
carbapenem-resistant



*Mycobacterium
tuberculosis*,
rifampicin-
resistant*

*RR-TB was included after
an independent analysis
with parallel criteria and
subsequent application of
an adapted MCDA matrix.

High group



Salmonella Typhi
fluoroquinolone-resistant



Shigella spp.
fluoroquinolone-resistant



*Enterococcus
faecium*
vancomycin-resistant



*Pseudomonas
aeruginosa*
carbapenem-resistant



Non-typhoidal
Salmonella
fluoroquinolone-resistant



*Neisseria
gonorrhoeae*
third-generation
cephalosporin, and/or
fluoroquinolone-resistant



*Staphylococcus
aureus*
methicillin-resistant

Medium group



Group A
Streptococci
macrolide-resistant



*Streptococcus
pneumoniae*
macrolide-resistant



*Haemophilus
influenzae*
ampicillin-resistant




Group B
Streptococci
penicillin-resistant

Bad Bugs, No Drugs: No ESKAPE! An Update
from the Infectious Diseases Society of America

Helen W. Boucher,¹ George H. Talbot,² John S. Bradley,^{3,4} John E. Edwards, Jr.,^{5,6,7} David Gilbert,⁸ Louis B. Rice,^{9,10}
Michael Scheld,¹¹ Brad Spellberg,^{3,6,7} and John Bartlett¹²


ESKAPEE



*Enterococcus
faecium/faecalis*



*Staphylococcus
aureus*



*Klebsiella
pneumoniae*



*Acinetobacter
baumannii*



*Pseudomonas
aeruginosa*



*Enterobacter
species*



*Escherichia
coli*

6 of the 18 most alarming
antimicrobial resistance
threats cost the U.S. more
than **\$4.6 billion annually**⁸

Vancomycin-resistant
Enterococcus (VRE)



Carbapenem-resistant
Acinetobacter species



Methicillin-resistant
Staphylococcus aureus (MRSA)




Carbapenem-resistant
Enterobacteriales (CRE)



Multidrug-resistant (MDR)
Pseudomonas aeruginosa



Extended-spectrum
cephalosporin resistance in
Enterobacteriales suggestive of
extended-spectrum β -lactamase
(ESBL) production






Finanziato
dall'Unione europea
NextGenerationEU



Ministero
dell'Università
e della Ricerca



Italiadomani
PIANO NAZIONALE
DI RIPRESA E RESILIENZA



Pseudomonas aeruginosa

- **Ranked # 1 in lung infection of cystic fibrosis (CF) patients (1:2,500 newborns)**
- Ranked # 1 in intensive care unit (ICU) infections
- Ranked # 3 in non-ICU hospital-acquired (HA) infections
- Ranked # 2 in HA bacterial pneumonia
- Severity of infection
- Intrinsic antibiotic resistance
- Acquired antibiotic resistance (HGT)
- **Pan-resistance in nosocomial and CF strains**

6 of the 18 most alarming
antimicrobial resistance
threats cost the U.S. more
than **\$4.6 billion annually**⁸

Vancomycin-resistant
Enterococcus (VRE)



Carbapenem-resistant
Acinetobacter species



Methicillin-resistant
Staphylococcus aureus (MRSA)




Carbapenem-resistant
Enterobacterales (CRE)



Multidrug-resistant (MDR)
Pseudomonas aeruginosa



Extended-spectrum
cephalosporin resistance in
Enterobacterales suggestive of
extended- spectrum β -lactamase
(ESBL) production






Finanziato
dall'Unione europea
NextGenerationEU



Ministero
dell'Università
e della Ricerca



Italiadomani
PIANO NAZIONALE
DI RIPRESA E RESILIENZA



Pseudomonas aeruginosa

- **Ranked # 1 in lung infection of cystic fibrosis (CF) patients (1:2,500 newborns)**
- Ranked # 1 in intensive care unit (ICU) infections
- Ranked # 3 in non-ICU hospital-acquired (HA) infections
- Ranked # 2 in HA bacterial pneumonia
- Severity of infection
- Intrinsic antibiotic resistance
- Acquired antibiotic resistance (HGT)
- **Pan-resistance in nosocomial and CF strains**



Need for new therapeutic options

6 of the 18 most alarming
antimicrobial resistance
threats cost the U.S. more
than **\$4.6 billion annually**⁸

Vancomycin-resistant
Enterococcus (VRE)



Carbapenem-resistant
Acinetobacter species



Methicillin-resistant
Staphylococcus aureus (MRSA)




Carbapenem-resistant
Enterobacterales (CRE)



Multidrug-resistant (MDR)
Pseudomonas aeruginosa



Extended-spectrum
cephalosporin resistance in
Enterobacterales suggestive of
extended- spectrum β -lactamase
(ESBL) production





Finanziato
dall'Unione europea
NextGenerationEU




Ministero
dell'Università
e della Ricerca



Italiadomani
PIANO NAZIONALE
DI RIPRESA E RESILIENZA

L-cysteine is fundamental for many biological processes





Finanziato
dall'Unione europea
NextGenerationEU





Ministero
dell'Università
e della Ricerca



Italiadomani
PIANO NAZIONALE
DI RIPRESA E RESILIENZA

L-cysteine is fundamental for many biological processes



ACS
chemical
biology

First-in-Class Inhibitors of Sulfur Metabolism with Bactericidal Activity against Non-Replicating *M. tuberculosis*

Prakash B. Palde,¹ Ashima Bhaskar,¹ Laura E. Pedró Rosa,² Franck Madoux,² Peter Chase,² Vinayak Gupta,¹ Timothy Spicer,² Louis Scampavia,² Amit Singh,² and Kate S. Carroll^{1,7}

¹Department of Chemistry, The Scripps Research Institute, Jupiter, Florida 33458, United States

²Department of Microbiology and Cell Biology (MCBL), Center for Infectious Disease Research (CIDR), Indian Institute of Science (IISc), Bangalore 560012, India

³and Identification Division, The Scripps Research Institute, Jupiter, Florida 33458, United States

CellPress

pharmaceuticals

MDPI

Article

Discovery of Substituted (2-Amino-oxazol-4-yl)isoxazole-3-carboxylic Acids as Inhibitors of Bacterial Serine Acetyltransferase in the Quest for Novel Potential Antibacterial Adjuvants

Joana Magalhães¹, Nina Franko², Samanta Raboni^{2,3}, Giannamaria Annunziato^{1,4}, Piivi Tammela⁵, Agostino Bruno¹, Stefano Bettati^{3,6,7}, Stefano Armao², Costanza Spadini², Clotilde Silvia Cabassi⁸, Andrea Mozzarelli^{2,3,7}, Marco Pieroni^{1,4,9}, Barbara Campanini² and Gabriele Costantino^{1,4}

ACS
Infectious
Diseases

pubs.acs.org/journal/aidcbe

Article


Investigational Studies on a Hit Compound Cyclopropane-Carboxylic Acid Derivative Targeting *O*-Acetylserine Sulfhydrylase as a Colistin Adjuvant

Giannamaria Annunziato,^{*,} Costanza Spadini,[○] Nina Franko, Paola Storici, Nicola Demitri, Marco Pieroni, Sara Flisi, Lucrezia Rosati, Mattia Iannarelli, Marialaura Marchetti, Joana Magalhães, Stefano Bettati, Andrea Mozzarelli, Clotilde Silvia Cabassi, Barbara Campanini, and Gabriele Costantino



L-cysteine metabolism as target for antibiotic development

Bacteria, differently from humans, are able to synthesise aminoacids, including L-Cys, from inorganic salts. The pathway has been characterized in Mycobacteria and some gram-negative bacteria...
...but it has been overlooked in *Pseudomonas aeruginosa*



ENHANCE
dE Novo L-cysteine biosynthesis in *Pseudomonas aeruginosa*:
pathWAY Assessment for novel aNTibiotic discOvery




Martedì R., D'Angelo J., Sassi G., Marchetti M., Hijazi S., Percudani R., Bettati S., Campanini B., Frangipani E. *De novo* cysteine biosynthesis in *Pseudomonas aeruginosa*: characterization of the two main cysteine synthase isoforms. *Under review in iScience*.



L-cysteine metabolism as target for antibiotic development

Bacteria, differently from humans, are able to synthesise aminoacids, including L-Cys, from inorganic salts. The pathway has been characterized in Mycobacteria and some gram-negative bacteria...
...but it has been overlooked in *Pseudomonas aeruginosa*



ENHANCE
dE Novo L-cysteine biosynthesis in *Pseudomonas aeruginosa*:
pathWay Assessment for novel aNtibiOtic discOvery




Martedì R., D'Angelo J., Sassi G., Marchetti M., Hijazi S., Percudani R., Bettati S., Campanini B., Frangipani E. *De novo* cysteine biosynthesis in *Pseudomonas aeruginosa*: characterization of the two main cysteine synthase isoforms. *Under review in iScience*.



L-cysteine metabolism as target for antibiotic development

CysH crystal structure is available

Gene	PAdb ID	Identity with <i>E. coli</i> ortholog
<i>cysD</i>	PA4443	78 %
<i>cysN</i>	PA4442	56 %
<i>cysH</i>	PA1756	27 %
<i>cysI</i>	PA1838	22 %
<i>cysJ</i>	PA4513	32 %
<i>cysE</i>	PA3816	40 %
<i>cysK</i>	PA2709	71 %
<i>cysM</i>	PA0932	69 %



How could we assay inhibitor activity






CysH virtual screening

ACTIVITY



Enzyme in the **open/inactive conformation**

- ☐ Lack the C-terminal region in X-ray structures
- ☐ Missing catalytic C256



Enzyme in the **closed/active conformation**

- ☐ Prediction of the C-terminal region through AlphaFold2.





Finanziato
dall'Unione europea
NextGenerationEU




Ministero
dell'Università
e della Ricerca



Italiadomani
PIANO NAZIONALE
DI RIPRESA E RESILIENZA

Computational workflow retrieving APSR **covalent** inhibitors





Finanziato
dall'Unione europea
NextGenerationEU




Ministero
dell'Università
e della Ricerca



Italiadomani
PIANO NAZIONALE
DI RIPRESA E RESILIENZA

Results of virtual screening protocol



Strategies

- ❑ Retrieval of warheads with varied reactivity
- ❑ Acceleration of covalent docking via starting reactive docking poses
- ❑ Prioritization of compounds with Binding-Pose Metadynamics, prioritizing stable binding modes ($\text{RMSD} < 2\text{\AA}$)





CysH_{Pa} activity (and inhibition) can be investigated through different *in vitro* assays

Protein recombinant production in *E. coli* (C-terminal Strep-tag). Purification under **aerobic conditions**, good yields (30 mg/L)


O05927 · CYSH_PSEAE

<https://www.uniprot.org/uniprotkb/O05927/entry>

MLPFATIPATERNSAAQHQPSPMSQPFDLPALASSLADKSPQDILKA
AFEHFGDELWISFSGAEDVVLVDMAWKLNRNVKVFSLDTGRLHPETYS
FIDQVREHYGIAIDVLSPDPRLLLEPLVKEKGLFSFYRDGHGECCGIRK
IEPLKRKLAGVRAWATGQRRDQSPGTRSQVAVLEIDGAFSTPEKPLYK
FNPLSSMTSEEVWGYIIRMLELPYNSLHERGYISIGCEPCTRPLPNQH
EREGRWWEETHKECGLHAGNLIKAENLYFQ₁SAWSHPQFEK




- 1- marker
- 2- insoluble fraction
- 3- soluble fraction
- 4- flow through
- 5- wash
- 6- elution 1
- 7- elution 2
- 8- elution 3
- 9- final preparation






AMP detection:

AK/PK/LDH coupled assay – 340 nm






CysH is catalytically active and forms a covalent adduct with 319 that involves the catalytic cysteine






What we have done about **CysH** in *Pseudomonas aeruginosa*...




✗ We have successfully generated a **cysH in-frame deletion mutant** and characterized its phenotype




Generation of the deletion fragment
(containing the upstream and the downstream regions of cysH gene)



- Generation of a suicide plasmid containing the deletion of interest
- Transfer (conjugation) in *P. aeruginosa*
- Various subcultures....
- PCR/sequencing to confirm the mutation



```
CTAGAAAGGAATGGCGGGCGTCCCGGAATAGAAAAGAGCCCGCGTTCGCGGGGCTCTTCATCGGCGGCGGGTAC
AGGCTCAGCGAACGGCTGGAAGCCTTGAGGAACCTCGCGCTTGAGGTCTTCGTAGGTATGCACCGCGGGAACTGGGAAA
CTCGCGGATCACGTTTTCCGGGGCATGGAACAGGATCCCGCGCTGGGCTCGGAACGATGGTGGTGTCTGTAGGAAT
CGCCGGCGGGCATCACCGGATAGTAGGGCTCTTGAAGGCGATCACCGACTGCGGCTTGGGATCCCTTCGGCGCAATTGA
TAGCCGACACCGCGGTCTGCTGCTGATCTCCAGCTTGCGCAACACAGGGTCGGGAAGCCAGCTGGCGCATCAGCGG
CTGGGAGAACTCGTAGAAGGTGTGGAGAGAATCACCACTGGAAGCGCTCGCGCAGCCAGTCAAGTTCACCGCGCC
CTCCAGCGGGTTTCAAGGTGGCGATCACTCTGGATGTGCGCCAGCTTCAGGCCATGTTCGTGAGGATGGCAGGCGCG
TGCTTCATCAGCACGTCGTAGTCGGAATGTCGCGGGTGGTGGCTTCAGGGCGTCGATACCGGTTTTTTCGCGAACGC
GATCCAGATTTCCGGAACGACGCGCTTCAGGTCAGACAGGCAATTTCCGAGGACTCTCCTCGAAATCTCTGAAC
GATGGGTTGACGACGGAACGCGGCTCTAGCCCTCGCCGAGGCAAGGCAACGCGGCTTATCTGGAATCAAGGTCTG
ACAGGGGTAAATGTTATTTAGGGCCATTCGCTGCACTGACCGTCGATAGAGCGTATGCAATCGGGTAAAGTGGCGG
TCGAACCCCGAGCGGAGACCCAGCATGCGCATCACCATGGTCAAGAAAGTCTCGCCAACGGCGAGGACTGCCCAAGTG
CAAGGAAGTCCGGCAACGCTGGAACAGGCGGCTACCTGCGCGCATCCATCGCACCTTGGTGGCCGACGAACGCGACC
CGAACAGCGCAGGCTGGATGGTCCGCGCCAGTATGGCTAGAGACCGCGCGTCTTCGTGGTTGCGCACGACGACGGG
CGCGAACAGGTCTACACCGTGTTCATGAGCTTCTCCATGAAGTCTCGAACCGCGAGCGGAGAGGCGCGGACGCGCA
TCGGAACGGCTGGCCAGGCTGGCGGACGCGACAATCTCGACATGCTCTGAGGGCAGCCATGAAAGAGCCCGGACCA
GGCGGGGCTTTTCATGGGCGAGGCGATCAGTAGACCGGCGAGTTCGATGCGGTCGAACAACTCGTCCAGCTCGGGCTTG
TTGTGGCATTGCACGGCTTGGCCAGCAGCTCGCGGTGAGTGGCGAGCGAATTTCTCGATGAAGTCGCACATGAAGCC
CGCGAGGAAGGTGCGCGCGGGAAGCCGATCTTGGTCACGCTGGACTCGAACAGGTGGCTGGGTCGAGGATCACCAGGT
CGTTGTGAGCTTCGGATCGACCGCATGTGCGCCAGCATGCGACCCAGGCCAACCGCAGTAGGTCTTGATCAGC
TCGGCATCGGCGCGGTGAATACCACTTGGGCAAGCTT
```





Finanziato
dall'Unione europea
NextGenerationEU



Ministero
dell'Università
e della Ricerca



Italiadomani
PIANO NAZIONALE
DI RIPRESA E RESILIENZA

What we have done about **CysH** in *Pseudomonas aeruginosa*...



We successfully set-up the assay conditions






Growth in the M9 medium $\pm$ L-cysteine 40 $\mu\text{g/ml}$ (optimal L-cysteine concentration able to restore the growth of the *cysH* deletion mutant) can be considered as suitable test conditions for putative CysH-inhibitors




We have genetically complemented the *cysH* deletion mutant



Liquid medium



Solid medium





Finanziato
dall'Unione europea
NextGenerationEU



Ministero
dell'Università
e della Ricerca




Italiadomani
PIANO NAZIONALE
DI RIPRESA E RESILIENZA


CysH inhibitor assay to impair L-cysteine synthesis, hence *P. aeruginosa* growth



319



compound 319 on WT/pME6031 and $\Delta cysH$ /pMEcysH






Conclusions and future perspectives




- We have successfully identified a lead compound targeting *P. aeruginosa* CysH with good activity *in vitro* and in bacterial cells, in line with the primary aim of WP1 (*Development of a third party-accessible, enabling platform for efficient preclinical drug discovery*)



- We plan to solve CysH crystal structure in complex with 319 to gain insights on the functional and catalytic properties of the C-terminal region (in collaboration with Yvain Nicolet, IBS, Grenoble) and guide further med chem efforts



- Further validate the microbiological data on 319 by increasing the number of experimental replicates



- Assay 319 derivatives that possess the same warhead to investigate a putative increase in efficacy



Finanziato
dall'Unione europea
NextGenerationEU



Ministero
dell'Università
e della Ricerca



Italiadomani
PIANO NAZIONALE
DI RIPRESA E RESILIENZA

Acknowledgements

Molecular modeling

Giovanni Bottegoni
Gian Marco Elisi
Matilda Ymeraj

Microbiology

Emanuela Frangipani
Sarah Hijazi
Rebecca Martedì

Organic synthesis

Michele Mari

MS studies

Michele Menotta



Biochemistry

Barbara Campanini
Stefano Bettati
Marialaura Marchetti
Francesco Guggino



ENHANCE
dE Novo L-cysteine biosynthesis in *Pseudomonas aeruginosa*:
pathway Assessment for novel anTibiotic discovERY

The project is funded by:



Funded by
the European Union
NextGenerationEU



Ministero
dell'Università
e della Ricerca



Italiadomani
PIANO NAZIONALE
DI RIPRESA E RESILIENZA



UNIVERSITÀ
DI PARMA



UNIVERSITÀ
CARLO BO



Finanziato
dall'Unione europea
NextGenerationEU



Ministero
dell'Università
e della Ricerca



Italiadomani
PIANO NAZIONALE
DI RIPRESA E RESILIENZA





Grazie per l'attenzione



MODELING OF THE CATALYTIC PORTION OF APSR

- The **folding of the C-terminal tail** was predicted from its amino acid sequence using AlphaFold2.
- The **catalytic cysteine** is close to the sulfur atom of APS and to basic residues, such as K144 and arginine residues, that may increase cysteine nucleophilic proprieties.
- Comparison with **PAPS reductase**:
 - Conserved residues (ECG(I/L)H motif) are similarly positioned
 - Given the absence of the cluster Fe-S in the PAPS structure, its role may not be relevant for APSR mechanism.



2GOY – APSR (P. aeruginosa)
2OQ2 – PAPS (yeast)